An investigational IL-17C-specific antibody (MOR106) showed promising results in experimental studies for treatment of psoriasis and atopic dermatitis [47,48], however, phase II clinical trials for its use in atopic dermatitis were halted due to lack of efficacy (ClinicalTrials.gov Identifier NCT03568071). This evidence concerns the gene IL17C and atopic eczema.